Format

Send to

Choose Destination
J Med Chem. 2008 Nov 27;51(22):7049-52. doi: 10.1021/jm801050k.

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

Author information

1
Novartis Institutes for Biomedical Research, 4560 Horton Street, Emeryville, California 94608, USA. savithri.ramurthy@novartis.com

Abstract

A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties.

PMID:
18942827
DOI:
10.1021/jm801050k
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center